Form 8-K

8-K — Dare Bioscience, Inc.

Accession: 0001493152-26-037737

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0001401914

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001401914

2026-08-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 13,

2026

DARE

BIOSCIENCE, INC.

DARÉ

BIOSCIENCE, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-36395

20-4139823

(State

or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification No.)

3655

Nobel Drive, Suite

260

San Diego,

CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s

telephone number, including area code: (858)

926-7655

Not

Applicable

(Former name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock

DARE

Nasdaq

Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02

Results

of Operations and Financial Condition.

August 13, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the

quarter ended June 30, 2026, a copy of which is furnished as Exhibit 99.1 to this report.

The

information in this Item 2.02 and in Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject

to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange

Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation

by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

Item

9.01

Financial

Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press release issued on August 13, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

DARÉ

BIOSCIENCE, INC.

Dated:

August 13, 2026

By:

/s/

Sabrina Martucci Johnson

Name:

Sabrina

Martucci Johnson

Title:

President

and Chief Executive Officer

-3-

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Daré

Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Company

launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July

DARE

to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the third quarter of 2026, with prescriptions

and preorders already being accepted

Building

a commercial ecosystem to make it easier for women to discover, access and purchase products specifically designed for women

Clinical

pipeline continues to advance, led by positive interim Phase 3 Ovaprene® results and initiation of the DARE-HPV Phase 2 study

Company

to host conference call and webcast today, August 13, 2026, at 4:30 p.m. Eastern Time – Access the webcast here

SAN

DIEGO, August 13, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company

solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial

results for the quarter ended June 30, 2026, and provided a corporate update highlighting key milestones in its commercial evolution,

including the launch of Flora Sync LF5, its first directly commercialized product. The Company also continued preparations for prescription

dispensing of DARE to PLAY Sildenafil Cream and expanded its purpose-built commercial ecosystem.

Daré

continued to advance its diversified development pipeline of women’s health products toward multiple anticipated clinical and regulatory

milestones. The Company’s pipeline includes product candidates at various stages of development addressing significant unmet needs

across women’s health. As these programs move through clinical development and regulatory review, they have the potential to broaden

Daré’s future commercial portfolio, generate additional value-driving catalysts and provide a sustained pipeline of differentiated

products for its growing commercial infrastructure.

“The

launch of Flora Sync LF5, our first directly commercialized product, represents an important milestone in the strategy Daré has

pursued since its founding, to bring to market evidence-based products specifically designed for women,” said Sabrina Martucci

Johnson, President and Chief Executive Officer of Daré Bioscience. “With DARE to PLAY Sildenafil Cream nearing prescription

dispensing, we are expanding our commercial portfolio while building the capabilities to make our products easier for women to discover,

access and purchase. Our commercial platform is designed to support not only our initial launches, but also future products across our

portfolio. By pairing a differentiated women’s health pipeline with a scalable path to market, we are building a strong foundation

for sustainable, long-term growth.”

Daré

is building a commercial platform that brings together evidence-based products, provider engagement, targeted digital marketing, telehealth

services and the DARE Health Hub within a coordinated, data-driven model tailored to women’s health. These capabilities will allow

the Company to reach women through multiple channels, facilitate a more seamless path from education to fulfillment, and generate insights

that can inform customer acquisition and resource allocation. By applying the lessons from each launch across its broader portfolio,

Daré is creating a repeatable, capital-efficient approach to commercialization.

Building

Toward a Multi-Product Commercial Portfolio:

● Launched

Flora Sync LF5 through the DARE Health Hub, establishing the Company’s first direct-to-consumer

product offering.

● Continued

preparations for DARE to PLAY Sildenafil Cream prescription dispensing, with nationwide prescription

intake and early preorder activity underway through the DARE Health Hub.*

● DARE

to PLAY Sildenafil Cream prescription dispensing and initial product revenue expected to

commence in Q3 2026.

● Entered

a strategic collaboration with MyMenopauseRx to connect women exploring DARE to PLAY Sildenafil

Cream with a telehealth provider dedicated to perimenopause and menopause care and expand

patient access and reach.

● Continued

optimizing provider engagement, digital marketing, telehealth and customer acquisition channels

to support capital-efficient commercial growth.

● DARE

to RECLAIM – Estradiol plus Progesterone Monthly Hormone Therapy for Menopause*

○ Activities

to support commercial availability through the 503B compounding pathway are underway, with

prescription dispensing targeted to begin in 2027.

○ Working

in parallel to advance an FDA 505(b)(2) regulatory pathway strategy.**

Pipeline

Execution:

● Ovaprene®

- Investigational Hormone-Free Monthly Intravaginal Contraceptive

○ Reported

positive interim results from the ongoing pivotal Phase 3 study and the independent Data

Safety Monitoring Board’s recommendation that the study continue without modification.

● DARE-HPV

- Investigational Therapeutic with Potential to be the First for High-Risk HPV Infection

○ With

funding from an ARPA-H award, initiated a Phase 2 study expected to enroll approximately

100 women with persistent high-risk human papillomavirus (HPV) infection. Topline results

are expected in 2027.

○ Received

a funding award notice for a second $1.0 million tranche from the National Institute of Allergy

and Infectious Disease (NIAID), a division of the NIH, bringing the total funding award for

the DARE-HPV program across the project period that began in December 2024 to $2.0 million.

“We

are very pleased with the momentum across our development pipeline, including the recently reported positive interim results for Ovaprene

and the initiation of the DARE-HPV Phase 2 study,” continued Ms. Johnson. “We are also making meaningful progress across

our additional clinical and grant-supported programs, creating multiple opportunities for data, regulatory milestones and value creation.

Each step brings us closer to delivering new options in areas of women’s health where significant needs remain unmet.”

Financial

Results for Second Quarter 2026 and Highlights

Cash

Position

of June 30, 2026, Daré had approximately $12.6 million in cash and cash equivalents, and a working capital deficit, which is calculated

as current assets minus current liabilities, including a deferred grant funding liability of approximately $15.0 million, of approximately

$0.2 million.

Revenue

Total

revenue for the three months ended June 30, 2026 was $0.2 million compared to $(0.02) million for the same period of the prior year.

The increase is attributable to research and development (R&D) services revenues from agreements entered into with the Gates Foundation

in September and October 2025, partially offset by a decrease in non-cash royalty revenues related to XACIATO®.

Cost

of Revenues

Cost

of revenues for the three months ended June 30, 2026, was $0.3 million with no comparable activity in the same period of the prior year.

Cost of revenues related to the cost of performing R&D services under agreements entered into with the Gates Foundation in September

and October 2025, and to expenses associated with medical education and awareness related to the commercialization of DARE to PLAY.

Operating

Expenses

Selling,

general and administrative expenses were approximately $2.6 million for the three months ended June 30, 2026, compared to approximately

$2.4 million for the same period of the prior year. The year-over-year increase was primarily attributable to a non-cash write down of

previously deferred equity offering costs.

R&D

expenses were approximately $0.2 million for the three months ended June 30, 2026, compared to approximately $1.4 million for the same

period of the prior year. The decrease of approximately $1.2 million was primarily related to an increase in contra R&D expenses

for direct program costs, decreases in direct costs of several programs, driven by decreases in costs related to the Ovaprene Phase 3

clinical trial, the DARE-PTB1 program, and the DARE-LARC1 program, and a decrease in personnel-related costs. Such decreases were partially

offset by increases in expenses related to DARE-HPV, investigational Sildenafil Cream, and DARE to PLAY Sildenafil Cream. Contra R&D

expenses for the three months ended June 30, 2026 and 2025 primarily offset direct program costs for DARE-LARC1, Ovaprene and DARE-HPV.

Daré recognizes amounts received under grant and governmental funding awards as “contra-R&D expenses,” meaning

grant funding reduces R&D expenses in the statements of operations as the related costs are incurred over the grant period. Total

contra-R&D expense was approximately $4.7 million for the three months ended June 30, 2026, compared to approximately $4.5 million

for the same period of the prior year. Daré believes this dynamic is important to understand when evaluating the true scale of

Daré’s R&D investment and capital efficiency.

Revenue

Outlook

Daré

began recording revenue from sales of Flora Sync LF5 in July 2026 and expects to begin recording revenue from sales of DARE to PLAY Sildenafil

Cream in the third quarter of 2026. Revenue from DARE to RECLAIM estradiol and progesterone intravaginal ring is targeted to begin in

2027. Daré is building toward a multi-product revenue profile that diversifies and grows across 2026 and 2027.

Daré

encourages investors to review the detailed discussion of its financial statements, financial condition, liquidity, capital resources

and risk factors in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed today with the U.S. Securities and Exchange

Commission (SEC).

Conference

Call

Daré

will host a conference call and live webcast today, August 13, 2026, at 4:30 p.m. Eastern Time to review its financial results for the

quarter ended June 30, 2026, and to provide a company update.

access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 3808585.

The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the company’s

website at ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install

any necessary software. The webcast will be archived in the same section of the company’s website and available for replay for

90 days.

ABOUT

DARÉ BIOSCIENCE, INC.

Daré

Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between

promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous,

peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré

is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out”

or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline.

With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions

is lagging. Daré is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING

STATEMENTS

Daré

cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,”

“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”

“could,” “plan,” “potential,” “prepare,” “progress,” “seek,”

“should,” “would,” “build” or the negative version of these words and similar expressions.

this press release, forward-looking statements include, but are not limited to, statements relating to: Daré’s commercial

strategy and plans; the capabilities of Daré’s commercial infrastructure; the timing of DARE to PLAY and DARE to RECLAIM

prescription dispensing and product revenue; the market opportunity for Daré’s products and ability to gain market acceptance;

potential commercial portfolio expansion; the potential impact of the products that Daré brings to market for women and the Company;

development and regulatory pathway plans and expectations regarding Daré’s product candidates, including clinical development

strategies, clinical trial design, timelines, costs, milestones, and results, regulatory strategy; timing and outcome of FDA communications,

submissions and review of applications; the potential for Daré’s clinical development programs to generate value-driving

catalysts and provide a sustained pipeline of differentiated products; the sufficiency of non-dilutive grant and other financial award

funding to advance development of specified product candidates or programs, including through specified milestones; expectations regarding

existing collaborations and plans for future collaborations; and Daré’s ability to create meaningful long-term value for

women and shareholders.

Forward-looking

statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance

or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking

statements in this press release, including, without limitation, risks and uncertainties related to: Daré’s ability to raise

additional capital when and as needed to execute its business strategy and continue as a going concern; potential suspension and delisting

of Daré’s common stock from the Nasdaq Capital Market; Daré’s dependence on grants and other financial awards

from governmental entities and a private foundation; Daré’s reliance on Section 503B-registered outsourcing facilities and

other third parties to bring DARE to PLAY Sildenafil Cream and other solutions to market as compounded drugs or as consumer health products

and facilitate access to such products and the risk that those third parties do not perform as expected; difficulties in establishing

and sustaining relationships with third-party collaborators; the risk that the U.S. Food and Drug Administration (FDA) could stop permitting

Section 503B-registered outsourcing facilities to compound the drug substances in the proprietary formulations Daré intends to

bring or brings to market or changes the conditions under which those drug substances may be used in compounding or the compounded products

may be distributed; the ability of outsourcing facilities for Daré’s compounded products to maintain their registration

with the FDA under Section 503B; the timing of establishing, and ability to maintain, state-required licensure or registration to enable

fulfillment of prescriptions for DARE to PLAY Sildenafil Cream and other solutions brought to market via the Section 503B pathway; Daré’s

inexperience, as a company, in and limited infrastructure for commercializing products; the degree of market demand and acceptance for

the products Daré brings to market; competitive product launches; greater than expected costs to bring compounded drug products

to market and marketing costs; shifts in consumer spending or behavior; Daré’s reliance on third parties to manufacture

and conduct clinical trials and preclinical studies of its product candidates and commercialize XACIATO™ (clindamycin phosphate)

vaginal gel 2% and future FDA-approved products, if any; the risk that the FDA’s 505(b)(2) pathway for drug product approval in

the U.S. is not available for a product candidate as Daré anticipates; Daré’s ability to develop, obtain FDA or foreign

regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting,

conducting and completing clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; Daré’s

ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints,

to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates;

decisions not to make clinical study design modifications recommended by the FDA; Daré’s dependence on third parties to

conduct clinical trials and manufacture and supply clinical trial material and commercial product; the risks that positive findings in

early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical

studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results

for that study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may

not accept or agree with Daré’s interpretation of or conclusions regarding data from clinical studies of its product candidates;

the risk that even if a pivotal clinical study achieves its primary efficacy endpoint, the FDA may determine the data package is not

sufficient to support a favorable benefit-risk determination in a future marketing application; the risk that development of a product

candidate requires more clinical or nonclinical studies than Daré anticipates, or that the duration of a study or number of study

subjects must be significantly greater than anticipated; the loss of, or inability to attract, key personnel; product pricing and coverage

and reimbursement from third-party payors; Daré’s ability to retain its licensed rights to develop and commercialize a product

or product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive,

in-license agreements covering the critical patents and related intellectual property related to its product and product candidates;

Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; disputes or

other developments concerning Daré’s intellectual property rights; the lack of patent protection for the active ingredients

in certain of Daré’s product candidates which could expose its products to competition from other formulations using the

same active ingredients; product liability claims; governmental investigations or actions relating to Daré’s products or

product candidates or the business activities of Daré, its commercial collaborators or other third parties on which Daré

relies; changes in healthcare, pharmaceutical, consumer protection or privacy laws and regulatory policies; increased scrutiny from regulators;

global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and

disruptions in U.S. government policies and operations on Daré’s ability to raise additional capital or on Daré’s

operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar

events that compromise Daré’s technology systems and/or significantly disrupt Daré’s business or those of third

parties on which it relies.

Daré’s

forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to

be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed

description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities

and Exchange Commission (SEC), including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not

to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré undertakes

no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made,

except as required by law.

*The

terms DARE to PLAY and DARE to RECLAIM describe 503B compounded drug products. Compounded drug products are not approved by the FDA.

The FDA does not evaluate compounded drug products for safety, effectiveness, or quality. References to Section 503B, 503B, 503B compounding,

503B compounded product, and similar terms refer to Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) and the production

and supply of compounded drugs by Section 503B-registered outsourcing facilities without patient-specific prescriptions in accordance

with Section 503B. Section 503B-registered outsourcing facilities are subject to FDA inspection and required to compound drug products

under current Good Manufacturing Practice (cGMP) regulations to ensure quality, strength and consistency.

**The

term FDA 505(b)(2) regulatory pathway refers to Section 505(b)(2) of the FDCA, which enables an applicant to rely, in part, on the FDA’s

prior findings of safety and efficacy data for an existing product, or published literature, in support of the applicant’s new

drug application (NDA), providing an alternate path to FDA approval for new or improved formulations or new uses of previously approved

drugs.

Contact:

Daré

Bioscience Investor Relations

innovations@darebioscience.com

Source:

Daré Bioscience, Inc.

Daré

Bioscience, Inc. and Subsidiaries

Condensed

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Three

Months Ended June 30,

2026

2025

Revenue

Research

and development services and royalty revenue

$ 187,546

$ (21,172 )

Total

revenue

187,546

(21,172 )

Cost

of revenues

319,889

Operating

expenses

Selling,

general and administrative

2,593,671

2,377,866

Research

and development

241,966

1,428,762

Total

operating expenses

2,835,637

3,806,628

Loss

from operations

(2,967,980 )

(3,827,800 )

Other

expense

(14,793 )

(188,683 )

Net

loss

$ (2,982,773 )

$ (4,016,483 )

Foreign

currency translation adjustments

2,225

12,983

Comprehensive

loss

$ (2,980,548 )

$ (4,003,500 )

Loss

per common share - basic and diluted

$ (0.20 )

$ (0.45 )

Weighted

average number of shares outstanding:

Basic

and diluted

14,889,832

8,871,155

Daré

Bioscience, Inc. and Subsidiaries

Condensed

Consolidated Balance Sheets Data

June

30, 2026

(unaudited)

December

31, 2025

Cash

and cash equivalents

$ 12,617,594

$ 24,711,356

Working

capital

$ (236,457 )

$ 3,378,192

Total

assets

$ 22,370,109

$ 32,474,563

Total

stockholders’ (deficit) equity

$ (560,100 )

$ 2,842,634

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (2427 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-36395

Entity Registrant Name

DARE

BIOSCIENCE, INC.

Entity Central Index Key

0001401914

Entity Tax Identification Number

20-4139823

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3655

Nobel Drive

Entity Address, Address Line Two

Suite

260

Entity Address, City or Town

San Diego

Entity Address, State or Province

Entity Address, Postal Zip Code

92122

City Area Code

(858)

Local Phone Number

926-7655

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock

Trading Symbol

DARE

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration